直接口服抗凝剂: 一种针对阿尔茨海默病的新疗法?
K Grossmann - 中国神经再生研究(英文版), 2021 - sjzsyj.com.cn
… inhibitor dabigatran etexilate and the blood clotting factor Xa-inhibitors rivaroxaban, apixaban…
In contrast to factor Xa-inhibitors, which block the production of thrombin, dabigatran binds …
In contrast to factor Xa-inhibitors, which block the production of thrombin, dabigatran binds …
7 种新型口服抗凝药预防全髋, 膝关节置换术后静脉血栓栓塞症的网状Meta 分析
杨婕， 温华， 马冰， 孙晶 - Journal of Pharmaceutical Practice …, 2018 - search.ebscohost.com
… Following findings ,directly ,Rivaroxaban and Apixaban were more effective than low …
A dose唱finding study with T AK唱442 an oral factor Xa inhibitor in patients undergo唱 ing …
A dose唱finding study with T AK唱442 an oral factor Xa inhibitor in patients undergo唱 ing …
新型口服抗凝血劑於侵入性手術時之建議
吳青柳， 陳冠群， 尹居浩 - 台灣醫學, 2014 - airitilibrary.com
… ) were now available in Taiwan including direct factor Xa inhibitor (rivaroxaban) and direct
thrombin inhibitor (dabigatran). The properties of the new oral anticoagulants are distinct from …
thrombin inhibitor (dabigatran). The properties of the new oral anticoagulants are distinct from …
直接Xa 因子抑制剂预防全膝关节置换后深静脉血栓的Meta 分析
陈学青， 贾健 - 中国组织工程研究, 2013 - cjter.com
… : Direct factor Xa inhibitors play an important role in the prevention and treatment of venous
thromboembolism. However, the efficacy and safety of direct factor Xa inhibitors … Apixaban or …
thromboembolism. However, the efficacy and safety of direct factor Xa inhibitors … Apixaban or …
关节置换术后抗凝药物预防深静脉血栓及相关并发症的临床研究进展.
徐祎骏， 肖军， 张洋， 史占军 - Progress in Modern …, 2016 - search.ebscohost.com
… , the direct thrombin inhibitor dabigatran, and the selective factor Xa inhibitors rivaroxaban
and apixaban, reviewing their clinical experience and latest advances in patients who have …
and apixaban, reviewing their clinical experience and latest advances in patients who have …
[HTML][HTML] 利伐沙班对预防肺癌相关肺血栓栓塞的研究进展
杨玉婷， 杨华 - Advances in Clinical Medicine, 2021 - hanspub.org
… Rivaroxaban, a new oral anticoagulant, is the earliest direct factor Xa inhibitor on the market
in China, and has greater advantages over traditional low-molecular-weight heparin and …
in China, and has greater advantages over traditional low-molecular-weight heparin and …
新型口服抗凝血剂在心房颤动患者中胃肠道出血和颅内出血的风险分析: 系统回顾和网络meta 分析
W Xu, S Hu, T Wu, AW Xu, AS Hu… - Journal of Zhejiang …, 2017 - jzus.zju.edu.cn
… We further ranked the NOACs for the lowest risk of GIB (apixaban 5 mg) and ICH (apixaban
5 mg, dabigatran 110 mg, and edoxaban 30 mg). Conclusions: Bayesian network meta-…
5 mg, dabigatran 110 mg, and edoxaban 30 mg). Conclusions: Bayesian network meta-…
[PDF][PDF] 新型口服抗凝药的特点和临床研究
周建光， 周颖奇 - 临床药物治疗杂志, 2013 - lcywzlzz.com
… etexilate (direct thrombin inhibitor) and inhibition of factor Xa such as rivaroxaban, apixaban,
… Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with …
… Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with …
Plasma lipids affect dabigatran etexilate anticoagulation in rats with unbalanced diabetes mellitus: 在失衡的糖尿病大鼠中血脂可以影响达比加群酯的抗凝作用
… , both direct thrombin inhibitors and direct Factor Xa inhibitors exhibited similar benefits in …
of reducing major bleeding with DE and apixaban compared with warfarin, as reported in the …
of reducing major bleeding with DE and apixaban compared with warfarin, as reported in the …
[PDF][PDF] 心房颤动抗栓药物治疗进展
马长生 - 临床药物治疗杂志, 2011 - lcywzlzz.com
… Fortunately,the new oral anticOaguIants like dabigatran,ri— varoxaban,apixaban,etc,may
change the current status of antithrombotic therapy in AF patients.This re· … 阿哌沙班(apixaban) …
change the current status of antithrombotic therapy in AF patients.This re· … 阿哌沙班(apixaban) …